Today's noteworthy upgrades include: A.V. Homes (AVHI) upgraded to Buy from Neutral at Sterne Agee CRT... AB InBev (BUD) upgraded to Outperform from Underperform at CLSA... AbbVie (ABBV) upgraded to Overweight from Equal Weight at Morgan Stanley... Agnico Eagle (AEM) upgraded to Outperform from Neutral at Macquarie... Albemarle (ALB) upgraded to Buy from Neutral at Citi... AptarGroup (ATR) upgraded to Buy from Hold at Deutsche Bank... Astoria Financial (AF) upgraded to Buy from Hold at Sandler O'Neill... BP (BP) upgraded to Equal Weight from Underweight at Morgan Stanley... First Niagara (FNFG) upgraded to Neutral from Sell at Goldman... Genesee & Wyoming (GWR) upgraded to Outperform from Neutral at Macquarie... Golden Star Resources (GSS) upgraded to Market Perform from Underperform at BMO Capital... KeyCorp (KEY) upgraded to Buy from Neutral at Citi... Leidos (LDOS) upgraded to Buy from Hold at Drexel Hamilton... MGM Resorts (MGM) upgraded to Buy from Neutral at UBS... MSCI (MSCI) upgraded to Buy from Neutral at UBS... Mercer (MERC) upgraded to Outperform from Neutral at Credit Suisse... Navigant Consulting (NCI) upgraded to Outperform from Market Perform at Barrington... New York Community Bancorp (NYCB) upgraded to Buy from Hold at Sandler O'Neill... Nutrisystem (NTRI) upgraded to Buy from Neutral at Sidoti... RBS (RBS) upgraded to Outperform from Neutral at Exane BNP Paribas... Rackspace (RAX) upgraded to Buy from Neutral at BofA/Merrill... Ramco-Gershenson (RPT) upgraded to Buy from Hold at Wunderlich... Range Resources (RRC) upgraded to Buy from Neutral at Guggenheim... SM Energy (SM) upgraded to Buy from Neutral at Guggenheim... Virtus Investment (VRTS) upgraded to Hold from Sell at Sandler O'Neill... Wendy's (WEN) upgraded on value offering at RBC Capital.

Notable companies reporting before tomorrow's open, with earnings consensus, include Exxon Mobil (XOM), consensus $2.20... Chevron (CVX), consensus $2.87... AbbVie (ABBV), consensus $2.23... HCA Healthcare (HCA), consensus $5.01... Colgate-Palmolive (CL), consensus 81c... Charter (CHTR), consensus $7.92... AutoNation (AN), consensus $4.27.

AbbVie announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study that evaluated the efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis who had an inadequate response to systemic therapy or when use of those therapies was inadvisable. In the LEVEL UP study, upadacitinib showed superior efficacy versus dupilumab in the primary endpoint, demonstrating that a significantly higher proportion of patients simultaneously achieved both a 90% or greater reduction in Eczema Area and Severity Index and a Worst Pruritus Numerical Rating Scale of 0 or 1 at Week 16.